These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 30934020)

  • 1. Mutational pathway maps and founder effects define the within-host spectrum of hepatitis C virus mutants resistant to drugs.
    Raja R; Pareek A; Newar K; Dixit NM
    PLoS Pathog; 2019 Apr; 15(4):e1007701. PubMed ID: 30934020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naïve subjects.
    Vidal LL; Soares MA; Santos AF
    J Viral Hepat; 2016 Nov; 23(11):840-849. PubMed ID: 26775769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region.
    Irving WL; Rupp D; McClure CP; Than LM; Titman A; Ball JK; Steinmann E; Bartenschlager R; Pietschmann T; Brown RJ
    Antiviral Res; 2014 Oct; 110():52-9. PubMed ID: 25057759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: novel insights about targeted genotyping approaches.
    de Carvalho IM; Alves R; de Souza PA; da Silva EF; Mazo D; Carrilho FJ; Queiroz AT; Pessoa MG
    J Med Virol; 2014 Oct; 86(10):1714-21. PubMed ID: 25042789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning.
    Cuypers L; Libin P; Schrooten Y; Theys K; Di Maio VC; Cento V; Lunar MM; Nevens F; Poljak M; Ceccherini-Silberstein F; Nowé A; Van Laethem K; Vandamme AM
    Infect Genet Evol; 2017 Sep; 53():15-23. PubMed ID: 28499845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a.
    Palanisamy N; Danielsson A; Kokkula C; Yin H; Bondeson K; Wesslén L; Duberg AS; Lennerstrand J
    Antiviral Res; 2013 Jul; 99(1):12-7. PubMed ID: 23648709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin.
    Larrat S; Vallet S; David-Tchouda S; Caporossi A; Margier J; Ramière C; Scholtes C; Haïm-Boukobza S; Roque-Afonso AM; Besse B; André-Garnier E; Mohamed S; Halfon P; Pivert A; LeGuillou-Guillemette H; Abravanel F; Guivarch M; Mackiewicz V; Lada O; Mourez T; Plantier JC; Baazia Y; Alain S; Hantz S; Thibault V; Gaudy-Graffin C; Bouvet D; Mirand A; Henquell C; Gozlan J; Lagathu G; Pronier C; Velay A; Schvoerer E; Trimoulet P; Fleury H; Bouvier-Alias M; Brochot E; Duverlie G; Maylin S; Gouriou S; Pawlotsky JM; Morand P
    J Clin Microbiol; 2015 Jul; 53(7):2195-202. PubMed ID: 25926499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NS3 genetic variability in HCV genotype-1b isolates from liver specimens and blood samples of treatment-naive patients with chronic hepatitis C.
    Maimone S; Musolino C; Squadrito G; Raffa G; Pollicino T; Raimondo G
    Antivir Ther; 2013; 18(1):131-4. PubMed ID: 23547300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing.
    Takeda H; Ueda Y; Inuzuka T; Yamashita Y; Osaki Y; Nasu A; Umeda M; Takemura R; Seno H; Sekine A; Marusawa H
    Sci Rep; 2017 Mar; 7():45605. PubMed ID: 28361915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants.
    Verbinnen T; Fevery B; Vijgen L; Jacobs T; De Meyer S; Lenz O
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7548-57. PubMed ID: 26392483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
    Halfon P; Sarrazin C
    Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two years' persistence of naturally present substitution R155K within hepatitis C virus NS3 protease in the absence of protease inhibitor-based therapy.
    Colson P; Gérolami R
    J Infect Dis; 2011 May; 203(9):1341-2; author reply 1342-3. PubMed ID: 21459820
    [No Abstract]   [Full Text] [Related]  

  • 14. Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations.
    Sølund C; Krarup H; Ramirez S; Thielsen P; Røge BT; Lunding S; Barfod TS; Madsen LG; Tarp B; Christensen PB; Gerstoft J; Laursen AL; Bukh J; Weis N;
    PLoS One; 2014; 9(12):e113034. PubMed ID: 25438153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy.
    Dietz J; Rupp D; Susser S; Vermehren J; Peiffer KH; Filmann N; Bon D; Kuntzen T; Mauss S; Grammatikos G; Perner D; Berkowski C; Herrmann E; Zeuzem S; Bartenschlager R; Sarrazin C
    PLoS One; 2016; 11(6):e0156731. PubMed ID: 27281344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accounting for strain variations and resistance mutations in the characterization of hepatitis C NS3 protease inhibitors.
    Ehrenberg AE; Schmuck B; Anwar MI; Gustafsson SS; Stenberg G; Danielson UH
    J Enzyme Inhib Med Chem; 2014 Dec; 29(6):868-76. PubMed ID: 24517372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance of the HCV protease inhibitor-resistant mutant viral load assessed by ultra-deep pyrosequencing in treatment failure.
    Mohamed S; Bourliere M; Benali S; Oules V; Castellani P; Khiri H; Camus C; Penaranda G; Chiche L; Gonzalez D; Sayada C; Olive D; Halfon P
    J Clin Virol; 2016 May; 78():36-43. PubMed ID: 26971166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5.
    Vallet S; Viron F; Henquell C; Le Guillou-Guillemette H; Lagathu G; Abravanel F; Trimoulet P; Soussan P; Schvoerer E; Rosenberg A; Gouriou S; Colson P; Izopet J; Payan C;
    Antivir Ther; 2011; 16(7):1093-102. PubMed ID: 22024525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of pyrazinone based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease.
    Belfrage AK; Abdurakhmanov E; Kerblom E; Brandt P; Oshalim A; Gising J; Skogh A; Neyts J; Danielson UH; Sandström A
    Bioorg Med Chem; 2016 Jun; 24(12):2603-20. PubMed ID: 27160057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy.
    Vicenti I; Rosi A; Saladini F; Meini G; Pippi F; Rossetti B; Sidella L; Di Giambenedetto S; Almi P; De Luca A; Caudai C; Zazzi M
    J Antimicrob Chemother; 2012 Apr; 67(4):984-7. PubMed ID: 22258932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.